Copyright
©The Author(s) 2015.
World J Gastroenterol. Jun 21, 2015; 21(23): 7281-7288
Published online Jun 21, 2015. doi: 10.3748/wjg.v21.i23.7281
Published online Jun 21, 2015. doi: 10.3748/wjg.v21.i23.7281
Table 3 Summary of R0 resection rates
Reason for surgery | Residual disease | n (%)1 |
Curative | ||
No (radical surgery) | 26 (55.8) | |
Yes | 7 (13.5) | |
Unknown | 2 (3.9) | |
Not applicable | 4 (7.7) | |
Palliative | ||
No (radical surgery) | 2 (3.9) | |
Yes | 4 (7.7) | |
Unknown | 2 (3.9) | |
Not applicable | 1 (1.9) | |
Biopsy | ||
Yes | 1 (1.9) | |
Not applicable | 1 (1.9) | |
Unknown | ||
Unknown | 1 (1.9) | |
Not applicable | 2 (3.9) | |
Other | ||
Yes | 1 (1.9) | |
Not applicable | 2 (3.9) |
- Citation: Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World J Gastroenterol 2015; 21(23): 7281-7288
- URL: https://www.wjgnet.com/1007-9327/full/v21/i23/7281.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i23.7281